Clinical Trials for Prostatitis Caused by Escherichia coli
Currently, there is 1 ongoing clinical trial investigating new treatment options for prostatitis caused by Escherichia coli bacteria. This trial is focused on testing an antibiotic called fosfomycin for cases where the infection is resistant to multiple standard antibiotics. The study is taking place in Spain and aims to help patients with difficult-to-treat bacterial prostate infections.
Clinical trial locations
Study on Fosfomycin for Treating Acute Bacterial Prostatitis in Patients with Multidrug-Resistant E. coli
This clinical trial is evaluating a treatment for acute bacterial prostatitis, an infection of the prostate gland caused by bacteria. The study specifically focuses on infections caused by multidrug-resistant Escherichia coli, a type of bacteria that does not respond to many commonly used antibiotics. This condition causes sudden symptoms such as fever, chills, pelvic pain, and difficulty urinating, and requires prompt medical attention.
Who can join this study?
The trial is open to men aged 18 years or older who have been diagnosed with acute bacterial prostatitis. To participate, you must have a positive urine or blood culture showing the presence of E. coli bacteria. For the main treatment group, the bacteria must be multidrug-resistant but still sensitive to fosfomycin. There is also a control group for comparison, which includes men whose E. coli infection is sensitive to most antibiotics. Participants will be matched with others based on age and clinical diagnosis.
Who cannot join this study?
This study is only for men, so women cannot participate. Only adults aged 18 and older are eligible. People who are considered part of vulnerable populations, such as those who cannot make decisions for themselves, are not eligible for this trial.
What is the goal of this study?
The main goal of this research is to determine whether fosfomycin, an antibiotic taken by mouth, is effective in treating acute bacterial prostatitis caused by multidrug-resistant E. coli. The study will compare the results of patients taking fosfomycin with those receiving other approved treatments for infections caused by bacteria that are not resistant to multiple drugs. Researchers want to find out if fosfomycin can be a viable treatment option when standard antibiotics fail.
What medication is being tested?
The investigational drug in this trial is fosfomycin, an antibiotic that works by preventing bacteria from building their cell walls, which eventually kills the bacteria. Fosfomycin is given as an oral solution that can be taken by mouth. Before starting fosfomycin treatment, participants may receive 1 to 5 days of intravenous antibiotics to stabilize their condition. The study will monitor how well fosfomycin works over the treatment period, with the trial expected to conclude by December 31, 2026.
Summary
Currently, there is only one clinical trial available for patients with prostatitis caused by Escherichia coli, and it is being conducted in Spain. This trial focuses specifically on treating infections with multidrug-resistant bacteria, addressing an important medical challenge as antibiotic resistance becomes more common. The study is testing fosfomycin, an oral antibiotic that works differently from many conventional antibiotics, potentially offering a new treatment option for patients whose infections do not respond to standard therapies. The research is in Phase IV, meaning the medication has already been tested in earlier studies and is now being evaluated in a larger group of patients to confirm its effectiveness and safety in this specific condition.
